Finance
Biopharmaceutical company reports first quarter 2005 financial results
Published in Cancer Weekly, June 7th, 2005
For the first quarter of 2005, the company reported net income of $30.1 million or $0.28 per share on a fully diluted basis, compared with the first quarter of 2004 net loss of $20.2 million or ($0.24) per share.
The 2005 net income figure includes a nonrecurring gain of $40.9 million, recognizing the extinguishment of a long-term loan due to Genentech, Inc. (DNA) as part of a restructuring of XOMA's arrangement with Genentech with...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2005-06-07)
More Articles from Cancer Weekly
- Breast Cancer
African-American breast cancer deemed the more aggressive phenotype - Diagnostics
Computed tomography accurately guided core needle biopsy of tumors - Gastroenterology
Hydration volume associated with symptoms in terminally ill cancer patients - Lung Cancer
Investigation to develop lymph node map in lung cancer initiated - Pain Medicine
Edmonton Staging System for classifying cancer pain revised - Acute Lymphoblastic Leukemia
Company initiates phase I/II clinical trial of talotrexin in patients with ALL - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
